Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Related Articles by Review for PubMed (Select 15231013)

1.

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.

J Bone Miner Res. 2004 Aug;19(8):1270-5. Epub 2004 Apr 12.

PMID:
15231013
2.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

Lee WL, Chao HT, Cheng MH, Wang PH.

Maturitas. 2008 Jun 20;60(2):92-107. doi: 10.1016/j.maturitas.2008.04.009. Epub 2008 Jun 4. Review.

PMID:
18534794
3.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
4.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
5.
6.
7.

Skeletal and nonskeletal effects of raloxifene.

Gluck O, Maricic M.

Curr Osteoporos Rep. 2003 Dec;1(3):123-8. Review.

PMID:
16036075
8.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

9.

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

Palacios S.

Curr Med Res Opin. 2010 Jul;26(7):1553-63. doi: 10.1185/03007991003795873. Review.

PMID:
20429824
10.

Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.

Cranney A, Adachi JD.

Drug Saf. 2005;28(8):721-30. Review.

PMID:
16048357
11.

[Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events].

Inoue D.

Clin Calcium. 2010 Mar;20(3):331-8. doi: CliCa1003331338. Review. Japanese.

PMID:
20190362
12.

Long-term raloxifene for postmenopausal osteoporosis.

Recker RR, Mitlak BH, Ni X, Krege JH.

Curr Med Res Opin. 2011 Sep;27(9):1755-61. doi: 10.1185/03007995.2011.606312. Epub 2011 Jul 25. Review.

PMID:
21787127
13.

The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.

Lee WL, Cheng MH, Tarng DC, Yang WC, Lee FK, Wang PH.

J Chin Med Assoc. 2013 Jul;76(7):365-71. doi: 10.1016/j.jcma.2013.03.010. Epub 2013 May 9. Review.

PMID:
23664736
14.

Raloxifene reduces fractures in postmenopausal women with osteoporosis.

Reginster JY, Devogelaer JP.

Clin Orthop Relat Res. 2006 Feb;443:48-54. Review.

PMID:
16462425
15.

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.

Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.

Endocr Rev. 2002 Aug;23(4):524-8. Review.

PMID:
12202467
16.

Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.

Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L.

Ann Intern Med. 2009 Nov 17;151(10):703-15, W-226-35. doi: 10.7326/0003-4819-151-10-200911170-00147. Review.

PMID:
19920271
17.

The use of raloxifene in osteoporosis treatment.

D'Amelio P, Isaia GC.

Expert Opin Pharmacother. 2013 May;14(7):949-56. doi: 10.1517/14656566.2013.782002. Epub 2013 Mar 24. Review.

PMID:
23521229
18.

[Bazedoxifene as a new-generation SERM].

Ohta H.

Clin Calcium. 2011 Jan;21(1):34-42. doi: CliCa11013442. Review. Japanese.

PMID:
21187592
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk